Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00388193
Status:
COMPLETED
Last Update Posted:
2014-10-28
First Post:
2006-10-13
Brief Title:
Rituximab Combined With Chemotherapy in Burkitts Lymphoma
Sponsor:
PETHEMA Foundation
Organization:
PETHEMA Foundation
Study Overview
Official Title:
BurkimabStudy Multicenter of Optimization of the Treatment of LLA-B and the Burkitts Lymphoma in Adult Patients From 15 Years Old
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical trial is to prove the efficacy of the following new regimen treatment
Administration of anti-CD20 Rituximab combined with chemotherapy
Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics block C
Prophylactic administration of G-CSF after all chemotherapy cycles
local irradiation after 6 cycle if CNS was affected or if there are residual tumour
Administration of anti-CD20 Rituximab combined with chemotherapy
Combined treatment with high doses of methotrexate and high doses of cytarabine with conventional cytostatics block C
Prophylactic administration of G-CSF after all chemotherapy cycles
local irradiation after 6 cycle if CNS was affected or if there are residual tumour
Detailed Description:
Clinical Trial with a pharmaceutical speciality in new conditions to use
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None